Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

FDA Warns Abilify Linked to Compulsive Urges

By Drug Discovery Trends Editor | May 5, 2016

The Food and Drug Administration issued a warning on Tuesday that reports of compulsive binge-eating, shopping, gambling, and sex have been connected to the antipsychotic Abilify.

Abilify (aripiprazole) treats a range of mental disorders like schizophrenia, bipolar disorder, Tourette syndrome, and even irritability associated with autism.

An examination of the FDA Adverse Event Reporting System (FAERS) database revealed that there were an estimated 184 cases of patients experiencing these urges, with 167 cases occurring in the United States.

Pathological gambling proved to be the most common side effect, with 164 cases. This adverse event is currently listed on the drug’s label, but the agency said the current warning didn’t adequately explain the risk it noted, reports The Wall Street Journal.

As a result of this information, the FDA is updating the warning label on Abilify and its generic counterparts.

The note emphasizes that these compulsive urges are rare, and they cease to happen when patients either stop taking the drug or the initial dosage is lowered.

Patients and caregivers should pay attention to any of these urges that may arise and should immediately consult a healthcare professional to limit or prevent harm. Physicians and medical professionals should alert patients of these side effects and closely monitor these individuals in the event these urges arise. 

R&D 100 AWARD ENTRIES NOW OPEN:

Establish your company as a technology leader! For more than 50 years, the R&D 100 Awards have showcased new products of technological significance. You can join this exclusive community! Learn more.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50